FindTrial
Sign In

9% Soluzione per infusione

DRUG3 trials

Sponsors

CatalYm GmbH, Fondazione IRCCS Policlinico San Matteo, River 2 Renal Corp.

Conditions

Chronic Obstructive Pulmonary DiseaseMuscle invasive bladder cancer set to undergo radical cystectomy who cannot receive or refuse to receive cisplatin-based chemotherapyPatients at high risk for Cardiac Surgery Associated – Acute Kidney Injury (CSA-AKI) following coronary artery bypass graft (CABG)aortic surgeryinvolving cardiopulmonary bypass (CPB).or a combination of the abovevalve surgery

Phase 2

A multi-center Phase 2 study of neoadjuvant immunotherapy in combination with the anti-GDF-15 antibody visugromab (CTL-002) for the treatment of muscle invasive bladder cancer
Active, not recruitingCTIS2024-513957-55-00
CatalYm GmbHMuscle invasive bladder cancer set to undergo radical cystectomy who cannot receive or refuse to receive cisplatin-based chemotherapy
Start: 2023-07-21Target: 31Updated: 2025-07-02
A two-center, randomized, double-blind, placebo-controlled study of intravenous plasma-purified alpha-1 antitrypsin for hospitalized patients with COPD exacerbations (AECOPD study)
RecruitingCTIS2024-517613-33-00
Fondazione IRCCS Policlinico San MatteoChronic Obstructive Pulmonary Disease
Start: 2025-10-16Target: 36Updated: 2025-10-13
A Phase 2, Multi-center, Randomized, Dose-Ranging, Placebo-Controlled, Double-blind Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated - Acute Kidney Injury.
Not yet recruitingCTIS2025-523037-25-00
River 2 Renal Corp.aortic surgery, involving cardiopulmonary bypass (CPB)., or a combination of the above +2
Target: 390Updated: 2026-03-04